Evaluation of Pyroptosis-related Indicators in the Pathogenesis of Vitiligo:Across-sectional Comparative Study

Launched by SOHAG UNIVERSITY · Feb 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called vitiligo, which causes white patches on the skin due to the loss of pigment cells. Although vitiligo doesn't harm a person's health, it can affect their self-esteem and quality of life. Researchers want to understand how certain cell death processes, especially one called pyroptosis, may be involved in the development of vitiligo. By looking at specific indicators related to pyroptosis, they hope to learn more about how vitiligo progresses and find better ways to treat it.

To participate in this study, individuals must be at least 18 years old and diagnosed with vitiligo. However, people who are pregnant, breastfeeding, or currently taking certain medications or have other skin diseases will not be eligible. Participants will undergo assessments to help researchers learn more about the disease and its connection to the inflammatory process involved in pyroptosis. This study is currently not recruiting participants, so more information will be available once it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with vitiligo ≥ 18 years old, both male and female patients will be included.
• Exclusion Criteria:
• * Patients with the following criteria will be excluded from our study:
• • 1. Pregnancy and breast-feeding women
• • 2. patients on antioxidants or anti-inflammatory drugs
• • 3. Patients on topical/systemic treatment for vitiligo in the last 4weeks prior to enrollment in the study
• • 4. Patients with other dermatological diseases as psoriasis, lichen planus, viral infection, etc.
• • 5. Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer.